<DOC>
	<DOCNO>NCT01427777</DOCNO>
	<brief_summary>The thirty-six-month immunogenicity evaluation Quadrivalent HPV ( Types 6 , 11 , 16 , 18 ) L1 Virus-Like Particle ( VLP ) Vaccine Chinese female subject age 9 45 year male subject age 9 15 year .</brief_summary>
	<brief_title>3-year Immunogenicity Evaluation Quadrivalent HPV Vaccine China</brief_title>
	<detailed_description>All eligible subject enrol one visit . A medical history physical examination conduct subject . A 10 mL blood specimen collect . All Sera ship PPD Vaccines Biologics Laboratory US . The serum specimen test PPD Laboratory competitive Luminex immunoassay ( cLIA ) multiplexed HPV immunoassay . The purpose quadrivalent HPV cLIA multiplex detect neutralize antibody total IgG HPV virus-like particle ( VLPs ) , serotypes 6 , 11 , 16 , 18 , respectively .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Chinese subject participate V501030 Perprotocol population . Subject agree provide study personnel primary telephone number well alternate telephone number followup purpose . Subject willing give consent/assent . Subject concurrently enrol clinical study investigational agent may interfere evaluation study objective . Subject condition opinion investigator might interfere evaluation study objective Subject history know prior vaccination HPV vaccine , either active agent placebo receive vaccination V501030</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>